BioTek Instruments, Inc., announced record revenues and earnings for its third quarter ending October 1, 2007. Reporting strong sales of its multi-mode microplate instrumentation, the Company also experienced increasing demand for its blood grouping and typing analyzer distributed through an exclusive agreement with Immucor, Inc. (NASDAQ: BLUD), a global leader in providing automated instrument-reagent systems to the blood transfusion industry.

Additionally, BioTek benefited from activities and invested resources in their rapidly growing international market, further assisted by the weakening U.S. dollar.

For the nine months ending September 2007, the Company reported net revenue increases of 17% and operating income increases of 19% compared to the same period last year, maintaining a significant growth advantage compared to other companies within the marketplace.

Privately held BioTek Instruments, Inc., is headquartered in Winooski, VT as a worldwide leader in the design, manufacture, and sale of microplate instrumentation and software. The BioTek Instruments, Inc. instrumentation is used to accelerate the drug discovery process, to advance discoveries in genomics and proteomics, and to aid in the advancement of life science research.


For further information, contact:

Chere Griffin
Shaw & Todd Advertising and Marketing Communications
908-668-1106 x15
cgriffin@shawtodd.com